Login
$NVCT
$19.11 +$0.00 (0.0%) After hours

$NVCT SEC Filings

Filed On Filing
04 Nov 2026 10-Q
04 Nov 2026 8-K: Results of Operations and Financial Condition

In-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group transformed Nuvectis into a late-stage clinical development company.

28 Aug 2026 EFFECT
21 Aug 2026 FORM S-3
21 Aug 2026 8-K: Other Events

Nuvectis Pharma, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares ...

06 Aug 2026 SCHEDULE 13G
05 Aug 2026 Form 4: Carson Michael J., Vice President, Finance

Received 30,000 shares as a grant or award

04 Aug 2026 10-Q
04 Aug 2026 8-K: Results of Operations and Financial Condition

Completed in-licensing of ex-China rights to two potentially best-in-class compounds (NXP100 and NXP200) from Haisco Pharmaceutical Group (“Haisco”), transforming the company into a late-stage clinical development organization.

01 Jul 2026 Form 4: Mosseri Marlio Charles, 10% owner

Bought 50,000 shares ($916K)

01 Jul 2026 Form 4: Bentsur Ron, Director

Bought 12,500 shares ($250K)

30 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

As Representative of the several Underwriters listed on Schedule IA hereto

30 Jun 2026 424B5
29 Jun 2026 424B5
29 Jun 2026 8-K: Other Events

As previously disclosed, on May 9, 2025, Nuvectis Pharma, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”) pursuant to which the Company may sell, from time to time, at i...

23 Jun 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds

12 Jun 2026 Form 4: Hoberman Kenneth, Director

Received 35,000 shares as a grant or award

12 Jun 2026 Form 4: Kaplan Matthew L., Director

Received 35,000 shares as a grant or award

12 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On Thursday, June 11, 2026, at 10:00 a.m. Eastern Time, by means of an online meeting platform, Nuvectis Pharma, Inc. (the “Company”) held its 2026 Annual Meeting (the “Annual Meeting”).

12 Jun 2026 Form 4: Oliviero James F Iii, Director

Received 35,000 shares as a grant or award

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support